Searched for: in-biosketch:yes
person:merrij01
Headache in systemic lupus erythematosus: results from a prospective, international inception cohort study
Hanly, John G; Urowitz, Murray B; O'Keeffe, Aidan G; Gordon, Caroline; Bae, Sang-Cheol; Sanchez-Guerrero, Jorge; Romero-Diaz, Juanita; Clarke, Ann E; Bernatsky, Sasha; Wallace, Daniel J; Ginzler, Ellen M; Isenberg, David A; Rahman, Anisur; Merrill, Joan T; Petri, Michelle; Fortin, Paul R; Gladman, Dafna D; Fessler, Barri J; Alarcon, Graciela S; Bruce, Ian N; Dooley, Mary Anne; Steinsson, Kristjan; Khamashta, Munther A; Ramsey-Goldman, Rosalind; Manzi, Susan; Sturfelt, Gunnar K; Nived, Ola; Zoma, Asad A; van Vollenhoven, Ronald F; Ramos-Casals, Manuel; Aranow, Cynthia; Mackay, Meggan; Ruiz-Irastorza, Guillermo; Kalunian, Kenneth C; Lim, S Sam; Inanc, Murat; Kamen, Diane L; Peschken, Christine A; Jacobsen, Soren; Theriault, Chris; Thompson, Kara; Farewell, Vernon
OBJECTIVE: To examine the frequency and characteristics of headaches and their association with global disease activity and health-related quality of life (HRQOL) in patients with systemic lupus erythematosus (SLE). METHODS: A disease inception cohort was assessed annually for headache (5 types) and 18 other neuropsychiatric (NP) events. Global disease activity scores (SLE Disease Activity Index 2000 [SLEDAI-2K]), damage scores (Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index [SDI]), and Short Form 36 (SF-36) mental and physical component summary scores were collected. Time to first headache and associations with SF-36 scores were analyzed using Cox proportional hazards and linear regression models with generalized estimating equations. RESULTS: Among the 1,732 SLE patients enrolled, 89.3% were female and 48.3% were white. The mean +/- SD age was 34.6 +/- 13.4 years, duration of disease was 5.6 +/- 5.2 months, and length of followup was 3.8 +/- 3.1 years. At enrollment, 17.8% of patients had headache (migraine [60.7%], tension [38.6%], intractable nonspecific [7.1%], cluster [2.6%], and intracranial hypertension [1.0%]). The prevalence of headache increased to 58% after 10 years. Only 1.5% of patients had lupus headache, as identified in the SLEDAI-2K. In addition, headache was associated with other NP events attributed to either SLE or non-SLE causes. There was no association of headache with SLEDAI-2K scores (without the lupus headache variable), SDI scores, use of corticosteroids, use of antimalarials, use of immunosuppressive medications, or specific autoantibodies. SF-36 mental component scores were lower in patients with headache compared with those without headache (mean +/- SD 42.5 +/- 12.2 versus 47.8 +/- 11.3; P < 0.001), and similar differences in physical component scores were seen (38.0 +/- 11.0 in those with headache versus 42.6 +/- 11.4 in those without headache; P < 0.001). In 56.1% of patients, the headaches resolved over followup. CONCLUSION: Headache is frequent in SLE, but overall, it is not associated with global disease activity or specific autoantibodies. Although headaches are associated with a lower HRQOL, the majority of headaches resolve over time, independent of lupus-specific therapies.
PMID: 24166793
ISSN: 0004-3591
CID: 986562
ABIN1 dysfunction as a genetic basis for lupus nephritis
Caster, Dawn J; Korte, Erik A; Nanda, Sambit K; McLeish, Kenneth R; Oliver, Rebecca K; G'sell, Rachel T; Sheehan, Ryan M; Freeman, Darrell W; Coventry, Susan C; Kelly, Jennifer A; Guthridge, Joel M; James, Judith A; Sivils, Kathy L; Alarcon-Riquelme, Marta E; Scofield, R Hal; Adrianto, Indra; Gaffney, Patrick M; Stevens, Anne M; Freedman, Barry I; Langefeld, Carl D; Tsao, Betty P; Pons-Estel, Bernardo A; Jacob, Chaim O; Kamen, Diane L; Gilkeson, Gary S; Brown, Elizabeth E; Alarcon, Graciela S; Edberg, Jeffrey C; Kimberly, Robert P; Martin, Javier; Merrill, Joan T; Harley, John B; Kaufman, Kenneth M; Reveille, John D; Anaya, Juan-Manuel; Criswell, Lindsey A; Vila, Luis M; Petri, Michelle; Ramsey-Goldman, Rosalind; Bae, Sang-Cheol; Boackle, Susan A; Vyse, Timothy J; Niewold, Timothy B; Cohen, Philip; Powell, David W
The genetic factors underlying the pathogenesis of lupus nephritis associated with systemic lupus erythematosus are largely unknown, although animal studies indicate that nuclear factor (NF)-kappaB is involved. We reported previously that a knockin mouse expressing an inactive form of ABIN1 (ABIN1[D485N]) develops lupus-like autoimmune disease and demonstrates enhanced activation of NF-kappaB and mitogen-activated protein kinases in immune cells after toll-like receptor stimulation. In the current study, we show that ABIN1[D485N] mice develop progressive GN similar to class III and IV lupus nephritis in humans. To investigate the clinical relevance of ABIN1 dysfunction, we genotyped five single-nucleotide polymorphisms in the gene encoding ABIN1, TNIP1, in samples from European-American, African American, Asian, Gullah, and Hispanic participants in the Large Lupus Association Study 2. Comparing cases of systemic lupus erythematosus with nephritis and cases of systemic lupus erythematosus without nephritis revealed strong associations with lupus nephritis at rs7708392 in European Americans and rs4958881 in African Americans. Comparing cases of systemic lupus erythematosus with nephritis and healthy controls revealed a stronger association at rs7708392 in European Americans but not at rs4958881 in African Americans. Our data suggest that variants in the TNIP1 gene are associated with the risk for lupus nephritis and could be mechanistically involved in disease development via aberrant regulation of NF-kappaB and mitogen-activated protein kinase activity.
PMCID:3810087
PMID: 23970121
ISSN: 1046-6673
CID: 986522
Herpes zoster vaccination in SLE: a pilot study of immunogenicity
Guthridge, Joel M; Cogman, Abigail; Merrill, Joan T; Macwana, Susan; Bean, Krista M; Powe, Tiny; Roberts, Virginia; James, Judith A; Chakravarty, Eliza F
OBJECTIVE: Patients with systemic lupus erythematosus (SLE) are at increased risk of herpes zoster (HZ). Although a vaccine for HZ has been approved by the US Food and Drug Administration, its use in immunocompromised individuals remains controversial because it is a live-attenuated virus vaccine. We performed a pilot study of the immunogenicity of the HZ vaccine (Zostavax) in patients with SLE. METHODS: Ten patients with SLE and 10 control subjects >/= age 50 years participated in this open-label vaccination study. All were seropositive for varicella zoster virus (VZV). Patients with SLE were excluded for SLE Disease Activity Index (SLEDAI) > 4, or use of mycophenolate mofetil, cyclophosphamide, biologics, or > 10 mg prednisone daily. Followup visits occurred at 2, 6, and 12 weeks. Clinical outcomes included the development of adverse events, particularly HZ or vesicular lesions, and SLE flare. Immunogenicity was assessed with VZV-specific interferon-gamma-producing enzyme-linked immunospot (ELISPOT) assays and with antibody concentrations. RESULTS: All subjects were women. Patients with SLE were slightly older than controls (60.5 vs 55.3 yrs, p < 0.05). Median baseline SLEDAI was 0 (range 0-2) for patients with SLE. No episodes of HZ, vesicular rash, serious adverse events, or SLE flares occurred. Three injection site reactions occurred in each group: mild erythema or tenderness. The proportion of subjects with a > 50% increase in ELISPOT results following vaccination was comparable between both groups, although absolute SLE responses were lower than controls. Antibody titers increased only among controls following vaccination (p < 0.05). CONCLUSION: The HZ vaccination yielded a measurable immune response in this cohort of patients with mild SLE taking mild-moderate immunosuppressive medications. No herpetiform lesions or SLE flares were seen in this small cohort of patients. ClinicalTrials.gov ID:NCT01474720.
PMCID:3867792
PMID: 24037550
ISSN: 0315-162x
CID: 986532
Predictors Of Damage Accrual Over a 2 Year Period In a Large Multi-Racial/Ethnic Lupus Cohort [Meeting Abstract]
Clowse, Megan E. B. ; Grossman, Jennifer M. ; Merrill, Joan T. ; Askanase, Anca ; Dvorkina, Olga ; Lockshin, Michael D. ; Aranow, Cynthia
ISI:000325359206327
ISSN: 0004-3591
CID: 657132
Angiogenic Factor Dysregulation and Risk Of Adverse Pregnancy Outcome In Lupus Pregnancies [Meeting Abstract]
Salmon, Jane E. ; Kim, Mimi ; Guerra, Marta M. ; Lockshin, Michael D. ; Branch, Ware D. ; Petri, Michelle ; Laskin, Carl A. ; Merrill, Joan T. ; Sammaritano, Lisa R. ; Buyon, Jill P. ; Karumanchi, S. Ananth
ISI:000325359202270
ISSN: 0004-3591
CID: 657162
Co-stimulatory molecules as targets for treatment of lupus
Merrill, Joan T
Co-stimulatory molecules help to regulate interactions between T cells and antigen-presenting cells and may play an important role in the pathogenesis of lupus. Both work in murine models and some early studies in human lupus support further examination of these molecules as therapeutic targets. Complexities of lupus clinical trial variables may have hampered progress in this area but recent developments in the field may make interventional trials more feasible in the near future. To date biologics which provide direct blockade of interactions between CD40 and CD154, B7RP-1 and ICOS, and CD80 or CD86 with CD28 have been assessed in multicenter clinical trials. These data will be reviewed and critiqued.
PMID: 23680362
ISSN: 1521-6616
CID: 986492
Reply: To PMID 22556106 [Letter]
Grossman, Jennifer M; Hahn, Bevra H; McMahon, Maureen A; Fitzgerald, John D; Merrill, Joan T; Yazdany, Jinoos; Wallace, Daniel J; Ramsey-Goldman, Rosalind
PMID: 23495047
ISSN: 2151-464x
CID: 986432
Clinical associations of the metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort
Parker, Ben; Urowitz, Murray B; Gladman, Dafna D; Lunt, Mark; Bae, Sang-Cheol; Sanchez-Guerrero, Jorge; Romero-Diaz, Juanita; Gordon, Caroline; Wallace, Daniel J; Clarke, Ann E; Bernatsky, Sasha; Ginzler, Ellen M; Isenberg, David A; Rahman, Anisur; Merrill, Joan T; Alarcon, Graciela S; Fessler, Barri J; Fortin, Paul R; Hanly, John G; Petri, Michelle; Steinsson, Kristjan; Dooley, Mary-Anne; Manzi, Susan; Khamashta, Munther A; Ramsey-Goldman, Rosalind; Zoma, Asad A; Sturfelt, Gunnar K; Nived, Ola; Aranow, Cynthia; Mackay, Meggan; Ramos-Casals, Manuel; van Vollenhoven, Raymond F; Kalunian, Kenneth C; Ruiz-Irastorza, Guillermo; Lim, Sam; Kamen, Diane L; Peschken, Christine A; Inanc, Murat; Bruce, Ian N
BACKGROUND: The metabolic syndrome (MetS) may contribute to increased cardiovascular risk in systemic lupus erythematosus (SLE). We aimed to examine the association of demographic factors, lupus phenotype and therapy exposure with the presence of MetS. METHODS: The Systemic Lupus International Collaborating Clinics Registry for Atherosclerosis inception cohort enrolled recently diagnosed (<15 months) SLE patients from 30 centres across 11 countries from 2000. Clinical, laboratory and therapeutic data were collected according to a standardised protocol. MetS was defined according to the 2009 consensus statement from the International Diabetes Federation. Univariate and backward stepwise multivariate logistic regression were used to assess the relationship of individual variables with MetS. RESULTS: We studied 1686 patients, of whom 1494 (86.6%) had sufficient data to determine their MetS status. The mean (SD) age at enrolment and disease duration was 35.2 years (13.4) and 24.1 weeks (18.0), respectively. MetS was present at the enrolment visit in 239 (16%). In backward stepwise multivariable regression analysis, higher daily average prednisolone dose (mg) (OR 1.02, 95% CI 1.00 to 1.03), older age (years) (OR 1.04, 95% CI 1.03 to 1.06), Korean (OR 6.33, 95% CI 3.68 to 10.86) and Hispanic (OR 6.2, 95% CI 3.78 to 10.12) ethnicity, current renal disease (OR 1.79, 95% CI 1.14 to 2.80) and immunosuppressant use (OR 1.81, 95% CI 1.18 to 2.78) were associated with MetS. CONCLUSIONS: Renal lupus, higher corticosteroid doses, Korean and Hispanic ethnicity are associated with MetS in SLE patients. Balancing disease control and minimising corticosteroid exposure should therefore be at the forefront of personalised treatment decisions in SLE patients.
PMCID:3711497
PMID: 22945501
ISSN: 0003-4967
CID: 986402
Top 10 things to know about lupus activity measures
Thanou, Aikaterini; Merrill, Joan T
Accurately measuring lupus disease activity has been a demanding and still unresolved task, considering the complex multisystem nature of the disease and its variability over time and between patients. Various available tools for measurement of lupus disease activity may detect clinical improvement and/or deterioration and can be global or organ-focused. Several measures have demonstrated validity, reliability, and sensitivity to change in observational studies, and some were found useful in randomized controlled trials. Evaluation of their content and metric properties and critical review of their strengths and weaknesses facilitates selection of the appropriate tool according to the outcome of interest, and forms the basis for their optimization. In this review, we highlight recent progress in lupus disease activity measures and point to future directions in this field, with a focus on novel composite measurements derived by combining outcome measures in ways that might compensate for their individual deficiencies.
PMID: 23606072
ISSN: 1523-3774
CID: 986462
Variable association of reactive intermediate genes with systemic lupus erythematosus in populations with different African ancestry
Ramos, Paula S; Oates, James C; Kamen, Diane L; Williams, Adrienne H; Gaffney, Patrick M; Kelly, Jennifer A; Kaufman, Kenneth M; Kimberly, Robert P; Niewold, Timothy B; Jacob, Chaim O; Tsao, Betty P; Alarcon, Graciela S; Brown, Elizabeth E; Edberg, Jeffrey C; Petri, Michelle A; Ramsey-Goldman, Rosalind; Reveille, John D; Vila, Luis M; James, Judith A; Guthridge, Joel M; Merrill, Joan T; Boackle, Susan A; Freedman, Barry I; Scofield, R Hal; Stevens, Anne M; Vyse, Timothy J; Criswell, Lindsey A; Moser, Kathy L; Alarcon-Riquelme, Marta E; Langefeld, Carl D; Harley, John B; Gilkeson, Gary S
OBJECTIVE: Little is known about the genetic etiology of systemic lupus erythematosus (SLE) in individuals of African ancestry, despite its higher prevalence and greater disease severity. Overproduction of nitric oxide (NO) and reactive oxygen species are implicated in the pathogenesis and severity of SLE, making NO synthases and other reactive intermediate-related genes biological candidates for disease susceptibility. We analyzed variation in reactive intermediate genes for association with SLE in 2 populations with African ancestry. METHODS: A total of 244 single-nucleotide polymorphisms (SNP) from 53 regions were analyzed in non-Gullah African Americans (AA; 1432 cases and 1687 controls) and the genetically more homogeneous Gullah of the Sea Islands of South Carolina (133 cases and 112 controls). Single-marker, haplotype, and 2-locus interaction tests were computed for these populations. RESULTS: The glutathione reductase gene GSR (rs2253409; p = 0.0014, OR 1.26, 95% CI 1.09-1.44) was the most significant single SNP association in AA. In the Gullah, the NADH dehydrogenase NDUFS4 (rs381575; p = 0.0065, OR 2.10, 95% CI 1.23-3.59) and NO synthase gene NOS1 (rs561712; p = 0.0072, OR 0.62, 95% CI 0.44-0.88) were most strongly associated with SLE. When both populations were analyzed together, GSR remained the most significant effect (rs2253409; p = 0.00072, OR 1.26, 95% CI 1.10-1.44). Haplotype and 2-locus interaction analyses also uncovered different loci in each population. CONCLUSION: These results suggest distinct patterns of association with SLE in African-derived populations; specific loci may be more strongly associated within select population groups.
PMCID:3735344
PMID: 23637325
ISSN: 0315-162x
CID: 986482